Ohio AG targets 4 drug distributors in second opioid lawsuit

Attorney General Mike DeWine filed a lawsuit Monday against four drug distributors, alleging the companies created a public nuisance through unsafe distribution tactics that resulted in the oversupply of opioids in Ohio.

Advertisement

The suit names McKesson, Cardinal Health, AmerisourceBergen and Miami-Luken as defendants. The companies have previously denied similar charges made in multiple lawsuits filed on behalf of state, local and city governments, according to a report from Reuters.

“We believe the evidence will show that these companies ignored their duties as drug distributors to ensure that opioids were not being diverted for improper use,” Mr. DeWine said. “They knew the amount of opioids allowed to flow into Ohio far exceeded what could be consumed for medically-necessary purposes, but they did nothing to stop it.”

In May 2017, Mr. DeWine filed a lawsuit against five opioid manufacturers, accusing the companies of engaging in fraudulent marketing and subsequently fueling the opioid epidemic in Ohio.

More articles on opioids: 
Drug overdose deaths decline in 14 states: 5 things to know 
FDA to encourage pharma to sell medication-assisted treatments for opioid addicts 
New Jersey county opioid lawsuit targets former Purdue leaders

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.